Default company panoramic image
Logo

Telephus Medical LLC

We are developing TPH 101, a novel monoclonal antibody to prevent MRSA biofilm infections in patients with artificial hip or knee implants.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location San Diego, CA, USA
  • Currency USD
  • Employees 7
  • Website telephusmedical.com

Company Summary

We hold global, exclusive rights to two classes of monoclonal antibodies which inhibit bacterial enzymes critical for staph colonization of implanted devices. TPH 101 mimics the activity of an antibody found in some patients who successfully recover from septic joint revision surgery. The proposed indication is for prophylaxis in patients undergoing arthroplasty and other procedures where patients face high risk of staphylococcal infection.

Team

  • Default avatar
    Mark Joseph Benedyk
    President & CEO

    20 years Business & Corporate Development
    Products : Preclinical to Launch to Phase IV
    Strategic Planning, Strategic Marketing
    $800 MM in transactions, $170 MM in raises
    Pfizer, Ascenta, Optimer Pharmaceuticals, Vertex, Elan
    Infectious Disease, Neurology, Pain, Oncology, Rare Diseases
    Previous Head, The Pfizer Incubator, La Jolla, CA

    Education
    PhD, Genetics, The Rockefeller University
    BS, Molecular Biology and Botany, University of

Advisors

  • Default avatar
    Wilson Sonsini Goodrich & Rosati
    Lawyer
    Unconfirmed
    Default avatar
    Torrey Pines Management Services
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Private High Net Worth Individuals
    Unconfirmed
    Default avatar
    Key Thought Leaders in Orthopedic Surgery
    Unconfirmed
    Default avatar
    Wilson Sonsini Goodrich & Rosati
    Unconfirmed